Seeking Alpha

Medtronic Inc. (MDT)

  • Nov. 19, 2012, 3:56 PM
    As the appetite for waging war against Obamacare wanes, smaller fixes are starting to come into the limelight, and are becoming increasingly more realistic, as long as every minor issue doesn’t blow up into a full-scale battle. One small fight is now being picked by medical device companies, who are trying to use the debate to get ObamaCare's tax on medical devices repealed, and it appears that some Democrats may support that initiative.
    | Comment!
  • Nov. 19, 2012, 2:23 PM
    St. Jude Medical (STJ +2%) says its received European approval for its Portico heart valve replacement device. The approval gives STJ access to a burgeoning market for the devices, and the news gives a much-needed lift to the stock after a string of negative headlines in recent months has driven the stock down near 52-week lows. Since October alone, STJ has shaved nearly 17% off its market cap.
    | Comment!
  • Nov. 19, 2012, 8:57 AM
    Medtronic (MDT +0.8%) has apparently completed its $816M acquisition of China Kanghui Holdings (KH), a provider of orthopedic implants. "Kanghui brings Medtronic a broad product portfolio, a strong local research & development and manufacturing operation, (and) a vast China distribution network," says Medtronic's Chris O'Connell.
    | Comment!
  • Nov. 14, 2012, 9:59 AM
    Obamacare is set to "take a toll" on medical-equipment companies due to a "stealth tax" on medical devices, says Tom Lydon of ETF Trends. A number of companies in the sector are planning pre-emptive layoffs in anticipation of the tax, including Medtronic (MDT) and St. Jude (STJ). Other companies in the field include [[J&J]], ISRG and BSX. ETFs worth watching include IYH, XLV, IHI and XHE.
  • Nov. 13, 2012, 3:18 PM
    Edwards Lifesciences(EW +1.7%) says a U.S. Appeals Court has affirmed a 2010 federal jury decision that Medtronic (MDT +0.3%) is infringing the company's U.S. Andersen transcatheter heart valve patent, as well as an initial payment award to EW of $74M. The court also ordered the trial court to reconsider EW's request for a permanent injunction that would prohibit the sale of Medtronic's CoreValve system in the U.S.
    | Comment!
  • Nov. 6, 2012, 7:38 PM
    Medtronic (MDT) announces interim findings from clinical trials which show that biventricular pacing may offer a significant advantage and improved patient outcomes over conventional right ventricular pacing among pacemaker patients. The findings were presented as a late-breaking clinical trial at the American Heart Association's 2012 Scientific Sessions, and show a 27% relative risk reduction in the composite of death and healthcare utilization visits among patients requiring intravenous heart failure therapy.
    | 1 Comment
  • Nov. 5, 2012, 9:39 AM
    Bypass surgery is more effective than drug-coated stents in preventing heart attacks and deaths in diabetics with more than one diseased artery, a five-year study shows. However, there were more strokes among bypass patients. Still, the data could lead to changes in treatment recommendations for thousands of people, hurting the profits of stent makers such as Abbott Labs (ABT -0.3%), Boston Scientific (BSX) and Medtronic (MDT -0.2%).
    | Comment!
  • Oct. 25, 2012, 3:48 AM
    The integrity of research into Medtronic's (MDT) bone-growth protein Infuse, which is used in spine surgery, has been called into question by a Senate Finance Committee report that says the company was "heavily involved in drafting, editing and shaping the content of medical journal articles" about the product. Medtronics also paid $210M for unrelated work to the doctors who wrote the articles.
    | Comment!
  • Oct. 22, 2012, 9:48 AM
    Medtronic's (MDT +0.2%) CoreValve heart implant increased 1-year survival rates amongst patients in a study and it improved their quality of life. Separately, a trial of the company's Symplicity renal denervation treatment helped reduce blood pressure in patients with "treatment-resistant hypertension," who have a high risk of "various cardiovascular events."
    | Comment!
  • Oct. 3, 2012, 2:12 PM
    Medtronic (MDT +0.3%) says it's successfully completed the first phase of feasibility studies on its next-generation renal denervation system, which features a simultaneously firing multi-electrode catheter and advanced radio-frequency generator. A total of nine patients were treated with a 100% acute success rate in accessing the vessels and delivering therapy. The system is only in its investigational phase however, and isn't yet commercially available anywhere in the world.
    | Comment!
  • Sep. 28, 2012, 12:45 PM
    Midday top 10 gainers: BYFC +171.43%. DHRM +28.21%. CHC +22.24%. KH +21.35%. CYTX +19.17%. CT +18.53%. AZZ +13.84%. NAVR +12.5%. REDF +12.14%. PCYO +11.12%.
    Top 10 Losers: CTC -16.16%. ULTR -12.27%. ASTC -10.26%. ALCS -9.42%. CRVP -9.17%. PPHM -8.86%. ASTI -8.76%. ADTN -8.66%. VSCI -8.57%. IRDM -7.76%.
    | Comment!
  • Sep. 28, 2012, 5:41 AM
    Medtronic (MDT) agrees to pay $816M for China Kanghui, a provider of orthopedic implants in a deal that expands the U.S. company's presence in China. Medtronic's offer of $30.75/ADR represents a 22.5% premium to Kanghui close yesterday. Barclays analyst Jason Mann says Kanghui provides Medtronic with "access to thousands of hospitals...(in) the fastest growing orthopedic market." (PR)
    | Comment!
  • Sep. 26, 2012, 7:56 AM
    The EU proposes tougher standards on medical devices and implants after investigations showed hundreds of thousands of women were at risk from substandard silicone implants. Independent assessment of manufacturers and increased product testing could result from the new legislation.
  • Sep. 18, 2012, 11:58 AM
    An Appeals court has overturned a lower court ruling that found Medtronic (MDT +0.2%) did not infringe on Boston Scientific (BSX -1.4%) CRT patents, and has remanded the case for further proceedings. The appeals court says the lower court relied on a "legally incorrect allocation of the burden of proof" and incorrectly construed the claim terms in the suit.
    | Comment!
  • Aug. 27, 2012, 8:38 AM
    Medtronic's (MDT) Protect study confirms the long-term safety of drug-eluting coronary stents, which slowly release a drug to block cell proliferation. The trial, the largest ever for such products, used Medtronic's Endeavor stent and J&J's (JNJ) Cypher to test for stent thrombosis, when a blood clot forms inside the stent. (PR)
  • Aug. 24, 2012, 1:32 PM
    Medtronic (MDT +0.3%) receives FDA and CE Mark approval for its Arctic Front Advance cardiac cryoballoon for the treatment of paroxysmal atrial fibrillation. MDT has the only cryoballoon system currently on the market worldwide, which is purported to provide a more efficient approach to treating the condition than through point-by-point, radiofrequency ablation.
    | Comment!
Visit Seeking Alpha's
MDT vs. ETF Alternatives
Company Description
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.